Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Anemia Due to Chronic Kidney Disease
NCT07725497Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in anemia, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Hemoglobin improvement at 12 weeks. Started Jul 2026; status: recruiting.
02
Drugs
luspatercept
03
Conditions
anemia
Beyond the preview
Go deeper on NCT07725497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07725497.